Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition-Reference-Cited by-同舟云学术

Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition

Published:2021-09-17 Issue:19 Volume:64 Page:14230-14246
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pal Pratik¹,Thummuri Dinesh²,Lv Dongwen²,Liu Xingui²,Zhang Peiyi¹,Hu Wanyi¹,Poddar Saikat K.¹,Hua Nan²,Khan Sajid²,Yuan Yaxia²,Zhang Xuan¹,Zhou Daohong²,Zheng Guangrong¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, Florida 32610, United States

2. Department of Pharmacodynamics, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, Florida 32610, United States

Funder

National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00517

Reference38 articles.

1. Hallmarks of Cancer: The Next Generation

2. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

3. Death and anti-death: tumour resistance to apoptosis

4. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics

5. Apoptosis: A Review of Programmed Cell Death

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted degradation of specific TEAD paralogs by small molecule degraders;Heliyon;2024-09

2. Design, Synthesis, and Evaluation of BCL‐2 Targeting PROTACs;Chemistry – A European Journal;2024-07-25

3. Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN;Cell Reports Physical Science;2024-05

4. Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment;European Journal of Medicinal Chemistry;2024-03

5. mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation;MedComm;2024-02